What is Wegovy

Wegovy (semaglutide) is a prescription-only once-weekly injection that may be prescribed for weight management alongside a reduced-calorie diet and increased physical activity. It works by activating the GLP-1 receptor, a hormone involved in appetite regulation, which can help some people feel fuller and reduce hunger.

In clinical studies in adults with obesity (or overweight with weight-related health conditions), average weight reduction with semaglutide 2.4 mg alongside lifestyle measures was around 10% to 15% over about 68 weeks, although individual results vary.

More recent studies evaluating higher doses of semaglutide have reported average weight reductions of around 20% over about 72 weeks in people with obesity. Results depend on the dose used and the population studied, and weight loss varies between individuals.

Wegovy is injected once a week, on the same day each week. Each pre-filled pen contains a single weekly dose, so one pen is used each week. Dose increases should only be made according to the prescribed treatment plan following clinical review.

Eligibility (subject to clinical assessment)

Wegovy may be supplied to adults who:

• have a BMI of 30 kg/m² or above, or
• have a BMI of 27 kg/m² or above with at least one weight-related health condition (e.g. high blood pressure (hypertension), high cholesterol (dyslipidaemia), obstructive sleep apnoea, type 2 diabetes).

Supply is only available following an online consultation to check suitability, medical history and current medicines, and a clinician's approval.

Price and service

Pricing is shown upfront and includes the online or phone clinical assessment, the medication and delivery. There are no separate consultation or delivery fees.

Delivery and what's included

If approved, your medication is dispensed by a UK-registered pharmacy and delivered in validated temperature-controlled packaging designed to help maintain appropriate refrigerated conditions in transit. Your order includes needles and usage guidance; a sharps bin can be provided if needed.

Dosage

Wegovy uses a gradual, step-by-step dosing schedule to help your body adjust and minimize potential side effects as you progress to a higher, effective dose. You’ll start at a low dose and gradually increase it every four weeks until reaching your maintenance level.

Please select the Wegovy dose recommended in your personal treatment plan, starting with the 0.25 mg dose (this product). If you're unsure about the appropriate dosage, please consult our pharmacist (pharmacy@medino.com) before placing your order.

For individuals with a BMI over 50, we advise consulting with a doctor or specialist for a comprehensive treatment plan.

Patient information leaflet

Our service does not include a prescription. Instead, your treatment will be supplied under a legal framework called Patient Group Direction (PGD), and the process will follow these steps:

1. Complete a health questionnaire:

Provide detailed information about your health, medical history, and previous weight management attempts.

2. Pharmacist assessment:

Our pharmacist will review your responses and may reach out via phone or video call to confirm your suitability for Mounjaro.

3. Private consultation:

All consultations are private and confidential. This gives you the opportunity to ask questions and ensure Mounjaro is the right choice for your needs.

4. All-inclusive pricing:

The price you pay includes the consultation fee, with no hidden costs.

5. Identity verification:

You'll need to provide identification during the consultation to confirm that you are the intended user. This is required only during your first order.

6. Photographic evidence request:

You’ll be asked to submit photographic evidence of your weight, height, and relevant medical history to ensure safe and accurate consultation.

Purchasing this medication does not guarantee its supply. The decision if this medication is right for you will be made together with the pharmacist during your consultation, and ultimately the decision to supply the medication is with the pharmacist. Any orders found not suitable will be refunded.

Each dose contains 0.25mg of semaglutide in 0.37mL solution.

One pre-filled pen contains 1 mg (four doses) of semaglutide in 1.5 mL solution.

*Semaglutide is a human glucagon-like peptide-1 (GLP-1) analogue produced in Saccharomyces cerevisiae cells by recombinant DNA technology.

Other ingredients: Disodium phosphate, dihydrate Propylene glycol, Phenol, Hydrochloric acid (for pH adjustment), Sodium hydroxide (for pH adjustment), Water for injection.

4 needles are included in the box. Although we provide needles with every purchase, you can purchase additional needles.

Inject 0.25mg subcutaneously once per week for 4 weeks (28 days).

Wegovy FlexTouch pen is designed to be used with NovoFine or NovoTwist disposable needles up to a length of 8 mm - these are included in the box.

The day of weekly administration can be changed if necessary, as long as the time between two doses is at least 3 days (>72 hours). After selecting a new dosing day, once-weekly dosing should be continued.

Wegovy is for subcutaneous use only and should not be administered intravenously or intramuscularly.

It should be injected in the abdomen, thigh or upper arm. The injection site and timing can be changed without dose adjustment.

Wegovy should not be mixed with other medicinal products.

Gastrointestinal Effects:

Sometimes, this medicine might cause stomach issues. This can lead to dehydration in rare cases, which can affect your kidneys. If you notice any stomach problems, be aware of the risk of dehydration and make sure to drink enough water.

Acute Pancreatitis:

In rare cases, our medication can cause a problem with your pancreas called acute pancreatitis. It's essential to know the symptoms of this issue. If you ever suspect you have it, stop taking the medication and talk to your doctor. If it's confirmed, don't restart the medication. Be cautious if you've had pancreatitis before.

For Patients with Diabetes:

If you have diabetes, remember that this medication isn't a replacement for insulin.

Hypoglycemia in Patients with Diabetes:

If you have diabetes and you're taking this medication along with insulin or certain other diabetes drugs, you might be at a higher risk of low blood sugar (hypoglycemia). To reduce this risk, your doctor might adjust your insulin or other medications. We haven't studied adding this medication if you're already taking insulin.

Diabetic Retinopathy in Patients with Type 2 Diabetes:

If you have type 2 diabetes and you're using this medication, you should be aware that there's a slightly higher risk of complications with your eyes. Rapid improvement in your blood sugar control can sometimes temporarily worsen diabetic retinopathy. Make sure to keep a close eye on your eye health and follow your doctor's advice.

Populations Not Studied:

We don't have enough information about how this medication affects people with severe heart problems (New York Heart Association class IV) or people who are 75 years or older.

Sodium Content:

The medication has very little sodium, so you don't need to worry about your salt intake when using it.

Pregnancy and breastfeeding

This product should not be used during pregnancy and breastfeeding.

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious side effects

Common: may affect up to 1 in 10 people

• Complications of diabetic eye disease (diabetic retinopathy). If you have diabetes, you should inform your doctor if you experience eye problems, such as changes in vision, during treatment with this medicine.

Uncommon: may affect up to 1 in 100 people

• Inflamed pancreas (acute pancreatitis). Signs of inflamed pancreas may include severe and long-lasting pain in your stomach, which may move to your back. You should see your doctor immediately if you experience such symptoms.
• Kidney or bladder stones. Signs may include back or lower abdomen pain, difficulty in urination, or change in colour of your urine.

Rare: may affect up to 1 in 1,000 people

• Severe allergic reactions (anaphylactic reactions, angioedema). You should seek immediate medical help and inform your doctor straight away if you get symptoms such as breathing problems, swelling of the face, lips, tongue, and/or throat with difficulty swallowing, wheezing, fast heartbeat, pale and cold skin, feeling dizzy or weak.
• Hip fractures.

Not known (frequency cannot be estimated from the available data)

• Bowel obstruction. A severe form of constipation with additional symptoms such as stomach ache, bloating, vomiting, etc.

Other side effects

Very common: may affect more than 1 in 10 people

• headache
• feeling sick (nausea)
• being sick (vomiting)
• diarrhoea
• constipation
• stomach pain
• feeling weak or tiredThese usually go away over time.

Common: may affect up to 1 in 10 people

• feeling dizzy
• upset stomach or indigestion
• burping
• gas (flatulence)
• bloating of the stomach
• inflamed stomach (gastritis) – symptoms include stomach ache, nausea, or vomiting
• reflux or heartburn – also called gastro-oesophageal reflux disease
• gallstones
• hair loss
• injection site reactions
• change in the way food or drink tastes
• change in skin sensation
• low blood sugar (hypoglycemia) in patients with diabetes

The warning signs of low blood sugar may come on suddenly. They can include cold sweat, cool pale skin, headache, fast heartbeat, feeling sick (nausea) or very hungry, changes in vision, feeling sleepy or weak, feeling nervous, anxious, or confused, difficulty concentrating, or shaking.

Your doctor will tell you how to treat low blood sugar and what to do if you notice these warning signs. Low blood sugar is more likely to happen if you also take a sulfonylurea or insulin. Your doctor may reduce your dose of these medicines before you start using this medicine.

Uncommon: may affect up to 1 in 100 people

• fast heartbeat
• increase of pancreatic enzymes (such as lipase and amylase) shown in blood tests
• a delay in the emptying of the stomach
• low blood sugar (hypoglycemia) in patients without diabetes
• increased levels of bilirubin in your blood